NCT05062330View on ClinicalTrials.gov

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

August 28, 2021

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions
Dry Eye
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution administered 7 times over two consecutive days

Trial Locations (1)

02767

Andover Eye Associates (Raynham), Raynham

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY